182 related articles for article (PubMed ID: 9445192)
1. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
McLaren DB; McKenzie M; Duncan G; Pickles T
Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
[TBL] [Abstract][Full Text] [Related]
2. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations.
Ross PL; Mahmud S; Stephenson AJ; Souhami L; Tanguay S; Aprikian AG
Urology; 2004 Aug; 64(2):323-8. PubMed ID: 15302488
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
4. PSA doubling time of prostate carcinoma managed with watchful observation alone.
Choo R; DeBoer G; Klotz L; Danjoux C; Morton GC; Rakovitch E; Fleshner N; Bunting P; Kapusta L; Hruby G
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):615-20. PubMed ID: 11395227
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
6. The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting.
Arai Y; Egawa S; Kuwao S; Ogura K; Baba S
BJU Int; 2001 Dec; 88(9):909-14. PubMed ID: 11851612
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
10. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
[TBL] [Abstract][Full Text] [Related]
11. Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
Bangma CH; HOP WCJ ; Schröder FH
J Urol; 1995 Oct; 154(4):1403-6. PubMed ID: 7544841
[TBL] [Abstract][Full Text] [Related]
12. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
Vollmer RT; Egawa S; Kuwao S; Baba S
Cancer; 2002 Mar; 94(6):1692-8. PubMed ID: 11920530
[TBL] [Abstract][Full Text] [Related]
13. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
Coen JJ; Feldman AS; Smith MR; Zietman AL
BJU Int; 2011 May; 107(10):1582-6. PubMed ID: 20860650
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
[TBL] [Abstract][Full Text] [Related]
16. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
17. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
Egawa S; Matsumoto K; Suyama K; Iwamura M; Kuwao S; Baba S
Cancer; 1999 Aug; 86(3):463-9. PubMed ID: 10430254
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
20. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
